Clinical Trial Update: Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab combined with chemotherapy as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Yuankai Shi | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING